Erste Asset Management’s Keros Therapeutics KROS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $279K | Hold |
20,700
| – | – | ﹤0.01% | 717 |
|
|
2025
Q1 | $223K | Hold |
20,700
| – | – | ﹤0.01% | 469 |
|
|
2024
Q4 | $340K | Hold |
20,700
| – | – | ﹤0.01% | 466 |
|
|
2024
Q3 | $1.17M | Hold |
20,700
| – | – | 0.01% | 376 |
|
|
2024
Q2 | $933K | Hold |
20,700
| – | – | 0.01% | 378 |
|
|
2024
Q1 | $1.34M | Buy |
20,700
+15,000
| +263% | +$970K | 0.02% | 343 |
|
|
2023
Q4 | $234K | Hold |
5,700
| – | – | ﹤0.01% | 479 |
|
|
2023
Q3 | $186K | Hold |
5,700
| – | – | ﹤0.01% | 483 |
|
|
2023
Q2 | $227K | Hold |
5,700
| – | – | ﹤0.01% | 483 |
|
|
2023
Q1 | $240K | Hold |
5,700
| – | – | ﹤0.01% | 479 |
|
|
2022
Q4 | $274K | Hold |
5,700
| – | – | 0.01% | 465 |
|
|
2022
Q3 | $207K | Hold |
5,700
| – | – | ﹤0.01% | 495 |
|
|
2022
Q2 | $155K | Hold |
5,700
| – | – | ﹤0.01% | 528 |
|
|
2022
Q1 | $306K | Hold |
5,700
| – | – | 0.01% | 478 |
|
|
2021
Q4 | $318K | Hold |
5,700
| – | – | 0.01% | 470 |
|
|
2021
Q3 | $234K | Hold |
5,700
| – | – | ﹤0.01% | 468 |
|
|
2021
Q2 | $242K | Hold |
5,700
| – | – | ﹤0.01% | 464 |
|
|
2021
Q1 | $328K | Hold |
5,700
| – | – | 0.01% | 421 |
|
|
2020
Q4 | $425K | Buy |
+5,700
| New | +$425K | 0.01% | 402 |
|